Psychological co-morbidities in COPD: Targeting systemic inflammation, a benefit for both?

Pelgrim, Charlotte E.; Peterson, Julia D.; Gosker, Harry R.; Schols, A.M.W.J.; Helvoort, Ardy van; Garssen, Johan; Folkerts, Gert; Kraneveld, Aletta D.

doi:10.1016/j.ejphar.2018.10.001

Cited by 57 publications

(49 citation statements)

References 185 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Multiple studies with different sample sizes and cognitive-function assessment tools have determined that the prevalence of cognitive impairment (CI) in patients with COPD ranges from 17% to 56.7%, which is significantly higher than that in healthy controls (12%–12.7%). 2 CI in patients with COPD is mainly manifested in attention function, memory function, executive function, verbal fluency and mental-processing speed, 3–6 which affect physical performance, psychological functions and quality of life (QoL). 7 8 However, relevant research on the treatment of CI in patients with COPD is rare.…”

Section: Introductionmentioning

confidence: 99%

Effect of 12-week pulmonary rehabilitation on cognitive function in patients with stable chronic obstructive pulmonary disease: study protocol for a single-center randomised controlled trial

Duan

Wang

et al. 2020

BMJ Open

View full text Add to dashboard Cite

IntroductionCognitive impairment, an important complication in patients with chronic obstructive pulmonary disease (COPD), seriously affects self-management of the disease and quality of life (QoL). As an exercise-based intervention programme, pulmonary rehabilitation (PR)—especially aerobic exercise (mainly mind–body exercise) and resistance exercise (RE)—has been proposed for its potential effectiveness in improving cognitive function. However, there is still a lack of strong evidence for PR’s effectiveness. In this study, we expect to clarify the effects of pulmonary-based Qigong exercise and elastic band-based RE on cognitive function in patients with COPD and to fill in the relevant evidence blanks.Methods and analysisThis study is a single-centre randomised controlled trial with assessor and data analyst blinding. We will recruit 108 participants with stable COPD starting on 23 December 2019, and randomly allocate them into the pulmonary-based Qigong exercise group, elastic band-based RE group, pulmonary-based Qigong exercise and elastic band-based RE combined group, or control group at a 1:1:1:1 ratio. Participants in intervention groups will perform 30 min of exercise two times per day, 5 days a week, for 12 weeks. The primary outcome will be the global cognitive function as assessed by the Montreal Cognitive Assessment and auditory event-related potential P300. Secondary outcomes will include the specific cognitive domains—attention, memory, executive function, verbal fluency and mental-processing speed; psychological functions and QoL. Exploratory outcomes will include grey matter volume and levels of inflammatory mediators. Outcomes will be measured before and after the interventions.Ethics and disseminationEthics approval has been granted by the Ethics Committee of Yue-Yang Integrative Medicine Hospital, an affiliate of Shanghai University of Traditional Chinese Medicine, Shanghai, China (Grant No. 2019-141). Written informed consent will be obtained from each participant before any procedures are performed. The findings will be published in peer-reviewed journals and presented at academic conferences.Trial registration numberChiCTR1900026869; pre-results.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of 12-week pulmonary rehabilitation on cognitive function in patients with stable chronic obstructive pulmonary disease: study protocol for a single-center randomised controlled trial

Duan

Wang

et al. 2020

BMJ Open

View full text Add to dashboard Cite

show abstract

“…The impact of daily consumption of whey beverage fortified with magnesium and vitamin C on COPD-related quality of life by improving psychological functioning and respiratory symptoms was generally remarkable. Based on available evidence, psychological improvements might be related to the decreased inflammatory cytokines [ 55 ] and neuroprotective effect of magnesium [ 56 ]. Our findings appear to be well supported by these trials indicating desirable effects on COPD comorbidities.…”

Section: Discussionmentioning

confidence: 99%

Fortified whey beverage for improving muscle mass in chronic obstructive pulmonary disease: a single-blind, randomized clinical trial

et al. 2020

View full text Add to dashboard Cite

Background The development of effective nutritional supports for patients with chronic obstructive pulmonary diseases (COPD) is still challenging. This study was conducted to investigate the efficacy of daily consumption of fortified whey on inflammation, muscle mass, functionality, and quality of life in patients with moderate-to-severe COPD. Methods A single-blind, randomized trial study was performed on patients with COPD ( n = 46). Participants in the intervention group ( n = 23) daily received 250 ml of whey beverage fortified with magnesium and vitamin C for 8 weeks. Any changes in inflammatory cytokines (including interleukin- 6 (IL-6) and tumor necrosis factor (TNFα)) were the primary outcomes and the secondary outcomes were fat-free mass, handgrip strength, malnutrition, glutathione and malondialdehyde serum concentrations, and health-related quality of life (HRQoL). Body composition and muscle strength were measured by Bioelectrical Impedance Analysis (BIA) and hydraulic hand dynamometer, respectively. Fat-free mass index (FFMI) was also calculated. Results At the end of the study, 44 patients were analyzed. There were significant decreases in IL-6 concentrations in the intervention group compared to the control group. Also, FFMI, body protein, and handgrip strength increased significantly in the intervention group with significant changes between two groups. Moreover, improvement in health-related quality of life was observed in the intervention group compared to the control group. There were no significant changes in other study variables. Conclusions This novel nutritional intervention decreased inflammatory cytokines levels, improved indices of skeletal muscle mass and muscle strength, and ultimately, increased HRQoL in patients with moderate-to-severe COPD. Thus, it is suggested to do further studies to assess the effects of nutrition intervention on COPD progression. Trial registration IR.SUMS.REC.1396.85 ( https://www.irct.ir/ ).

show abstract

“…e results of the limited number of studies on the use of antidepressants and anxiolytic agents in the treatment of the anxiety and depressive disorders accompanying COPD are observed to vary [29]. It is observed that the use of benzodiazepine is frequently preferred, that the compliance with medication of the patients is generally low, and that the impacts of advanced age along with the impacts of other accompanying physical comorbidities are frequently observed and there are also conflicting data on the use of antidepressant treatments [29]. In our study, when the data of patients with psychiatric comorbid diagnoses were also evaluated, they were currently using antidepressant and anxiolytic therapies when they were included in the study.…”

Section: Discussionmentioning

confidence: 99%

Impacts of Coil Treatment on Anxiety and Depression in Emphysema

Uğurlu

2020

Canadian Respiratory Journal

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a widespread, preventable, and treatable disease. Emphysema is one of the primary components of COPD and manifests itself via decrease in elastic recoil, hyperinflation, and increase in air trapping. Various lung-volume-reduction treatments have come up in recent years for late-stage emphysema patients. Mental disorders and especially anxiety and depression are among the frequently encountered comorbid cases observed in COPD. The aim of our study was to examine the impact of coil treatment applied for late-stage COPD-emphysema diagnosed patients on the accompanying anxiety and depressive symptoms. A total of 21 patients diagnosed with emphysema that meet the suitability criteria for coil treatment were included in the study. The accompanying anxiety and depressive symptoms of the patients were assessed via beck anxiety inventory (BAI) and beck depression inventories (BDI-I) prior to the procedure and one month later. All patients were male with an age average of 66.5 ± 5.5 (57–76). Among patients without a psychiatric diagnosis, BAI scores before and after coil treatment were determined, respectively, as 12.1 ± 6.3 (4–26) and 11.2 ± 9.3 (0–28), whereas BDI-I scores before and after coil treatment were determined, respectively, as 13.5 ± 10.4 (1–31) and 8.8 ± 10.6 (0–34), with a statistically significant difference between them. Also among patients with a psychiatric diagnosis, both anxiety and depressive symptoms decreased after coil treatment, and this reduction was found more significant for anxiety. Coil treatment as a current and novel treatment method for COPD-emphysema diagnosed patients with or without psychiatric comorbidity has a positive impact on anxiety and depressive symptoms.

show abstract

Psychological co-morbidities in COPD: Targeting systemic inflammation, a benefit for both?

Cited by 57 publications

References 185 publications

Effect of 12-week pulmonary rehabilitation on cognitive function in patients with stable chronic obstructive pulmonary disease: study protocol for a single-center randomised controlled trial

Effect of 12-week pulmonary rehabilitation on cognitive function in patients with stable chronic obstructive pulmonary disease: study protocol for a single-center randomised controlled trial

Fortified whey beverage for improving muscle mass in chronic obstructive pulmonary disease: a single-blind, randomized clinical trial

Impacts of Coil Treatment on Anxiety and Depression in Emphysema

Contact Info

Product

Resources

About